From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Doctors and front-line workers are watching closely as HIV rates increase significantly in Alberta.An annual Alberta Health ...

With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Leerink has upgraded Gilead Sciences (NASDAQ:GILD) to outperform, citing the growth outlook for its PrEP treatment ...

On September 10, experts across disciplines, from infectious disease clinicians to regulators to representatives from the pharmaceutical industry, convened at the inaugural ImmunOptimize workshop in ...

Kidney stones cause a range of symptoms as they pass from the kidneys out of the body through the urethra. Learn about pain, ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...